Phase III trial of the anti-angiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy
Completed
- Conditions
- Malignant mesotheliomaCancerMesothelioma
- Registration Number
- ISRCTN13632914
- Lead Sponsor
- ederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT) (The Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 216
Inclusion Criteria
1. Good condition (Eastern Cooperative Oncology Group [ECOG] Performance Status [PS] zero to two)
2. First line therapy with pemetrexed minimum of four courses
3. A measurable lesion is not required
4. Normal laboratory values
5. Signed informed consent
6. Thalidomide therapy to start within nine weeks after last chemotherapy course
Exclusion Criteria
1. Inaqdequate measures for birth control
2. Polyneuropathy more than grade one
3. Thrombo-embolic events
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method